These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 11563406)

  • 21. Influence of cholestyramine on the pharmacokinetics of cerivastatin.
    Mück W; Ritter W; Frey R; Wetzelsberger N; Lücker PW; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):250-4. PubMed ID: 9208341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
    Plosker GL; Dunn CI; Figgitt DP
    Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Unger S; Kawano K; Ahr G
    Br J Clin Pharmacol; 1998 Jun; 45(6):583-90. PubMed ID: 9663814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the 0.8-mg dose of cerivastatin in patients with primary hypercholesterolemia.
    Stein E; Isaacsohn J; Stoltz R; Mazzu A; Liu MC; Lane C; Heller AH
    Am J Cardiol; 1999 May; 83(10):1433-6. PubMed ID: 10335757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of omeprazole pre- and cotreatment on cerivastatin absorption and metabolism in man.
    Sachse R; Ochmann K; Rohde G; Mück W
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):517-20. PubMed ID: 9799053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency.
    Chapelsky MC; Thompson-Culkin K; Miller AK; Sack M; Blum R; Freed MI
    J Clin Pharmacol; 2003 Mar; 43(3):252-9. PubMed ID: 12638393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.
    Mück W; Ritter W; Ochmann K; Unger S; Ahr G; Wingender W; Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):255-60. PubMed ID: 9208342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia.
    Nakamura T; Ushiyama C; Hirokawa K; Osada S; Shimada N; Koide H
    Am J Nephrol; 2001; 21(6):449-54. PubMed ID: 11799261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
    Kyrklund C; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2003 Jun; 73(6):538-44. PubMed ID: 12811363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man.
    Houin G; Brunner F; Nebout T; Cherfaoui M; Lagrue G; Tillement JP
    Br J Clin Pharmacol; 1983 Sep; 16(3):245-52. PubMed ID: 6626415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Controversy surrounding the safety of cerivastatin.
    Davidson MH
    Expert Opin Drug Saf; 2002 Sep; 1(3):207-12. PubMed ID: 12904136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment.
    Martin DE; Chapelsky MC; Ilson B; Tenero D; Boike SC; Zariffa N; Jorkasky DK
    J Clin Pharmacol; 1998 Feb; 38(2):129-37. PubMed ID: 9549643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor.
    Bischoff H; Angerbauer R; Bender J; Bischoff E; Faggiotto A; Petzinna D; Pfitzner J; Porter MC; Schmidt D; Thomas G
    Atherosclerosis; 1997 Nov; 135(1):119-30. PubMed ID: 9395280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry.
    Jemal M; Rao S; Salahudeen I; Chen BC; Kates R
    J Chromatogr B Biomed Sci Appl; 1999 Dec; 736(1-2):19-41. PubMed ID: 10676982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
    Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition and safety of omapatrilat in subjects with renal impairment.
    Sica DA; Liao W; Gehr TW; Khan S; Jemal M; Delaney CL; Ferreira IM; Malhotra BK
    Clin Pharmacol Ther; 2000 Sep; 68(3):261-9. PubMed ID: 11014407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
    Stern RH; Yang BB; Horton M; Moore S; Abel RB; Olson SC
    J Clin Pharmacol; 1997 Sep; 37(9):816-9. PubMed ID: 9549635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions.
    Mück W
    Drugs; 1998; 56 Suppl 1():15-23; discussion 33. PubMed ID: 9740537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
    Stangier J; Rathgen K; Stähle H; Mazur D
    Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.